HomeQuestion
What are your top takeaways from SABCS 2022?
3
5 Answers
Mednet Member
Medical Oncology · University of Texas MD Anderson Cancer Center
Here are my top 3 presentations (specifically for breast medical oncology) that I would say are most impactful (now or soon), with slides attached.
- GS3-04 - Capivasertib Phase III (CAPItello-291) Trial – these results will likely change standards for post CDKi progression for HR+/HER2-negative metas...
Mednet Member
Medical Oncology · Sarah Cannon Research Institute
- POSITIVE – appears that for women at least 18 months into endocrine therapy, stopping ET for up to 2 years in an attempt to have children doesn’t result in significantly worse outcomes. Very big clinical question that has been unanswered for some time.
- DB-03/DB-02 – firmly establishes TDXd as the m...
Mednet Member
Medical Oncology · UT Health San Antonio
- CAPItello-291 was one. First phase III trial showing benefit of adding AKT inhibitor to endocrine therapy. Maybe some toxicity concerns but this combination may become SOC in second line setting.
- EMERALD: new oral SERD with improved outcomes in ER+ HER2- MBC especially in ESR1 tumors.
- POSITIVE tria...
Mednet Member
Medical Oncology · Ohio State University
It is hard to choose the top 3 but I was intrigued by the following:
- MonarchE update - 4-year iDFS survival benefit with addition of 2 years of abemacicilib to adjuvant endocrine therapy in high risk, HR+/HER2- breast cancer.
- EMERALD trial, especially the superiority of elacestrant over fulvestran...
Mednet Member
Medical Oncology · Dana-Farber Cancer Institute
Here are my top 3:
- POSITIVE: Found that holding endocrine therapy to try to conceive did not impact the risk of recurrence with short term f/u (41 months). Important data for young women with ER+ breast cancer who desire children.
- DESTINY-Breast03: Updated analysis now has OS benefit (HR 0.64) and u...